Why NRx Pharmaceuticals Stock Soared Today

Why NRx Pharmaceuticals Stock Soared Today
·1 min read

Shares of NRx Pharmaceuticals (NASDAQ: NRXP) surged on Monday after the healthcare company released promising clinical trial data for its investigational COVID-19 treatment, aviptadil. An analysis conducted by respected statistician Dr. David Schoenfeld found that patients treated with aviptadil had a significantly higher probability of recovering from critical COVID-19 and respiratory failure than those who received existing therapies. Among those who previously received Gilead Sciences' (NASDAQ: GILD) remdesivir, patients treated with aviptadil were 2.5 times more likely to be alive and free of respiratory failure at 60 days than those who received a placebo.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting